1. Scrip
  2. >>Business
  3. >>Financing

Silverback Raises $78.5m To Test Localized Therapy Delivered Systemically In Patients

 
• By Mandy Jackson

The company will initiate a clinical trial this year for lead ADC candidate SBT6050, which links a HER2-targeting antibody to a TLR8 agonist to activate myeloid cells in the tumor and spur an immune response. 

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: venture capital
Silverback has raised more than $125m to date • Source: Shutterstock

With $78.5m in series B venture capital, Silverback Therapeutics Inc. will begin its first clinical trial later this year to determine whether its lead antibody-drug conjugate (ADC) SBT6050, which links a HER2-targeted antibody with a TLR8 agonist, will duplicate the company’s preclinical results that showed the ADC provided potent activation of myeloid cells and reprogrammed the tumor microenvironment.

Silverback has now raised more than $125m to date, including a series A extension that brought its initial funding round to $47.5m in September 2018 with the backing of founding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

More from Business

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.